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Abstract An oleate dependent form of phospholipase D is 
present in rat brain neuronal nuclei and both the hydrolytic and 
transphosphatidylation activities measured. Several acidic phos- 
pholipids were found to inhibit this activity in a dose dependent 
manner. The IC5o values varied from 3.5 ttM for PIP2 to 200 pM 
for phosphatidic acid. The hydrolysis of PIP2 by phospholipase C 
would be expected to result in the disinhibition of the oleate 
dependent phospholipase D activity. 
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1. Introduction 
There are two distinct forms of PLDs in mammalian tissues 
which hydrolyze PtdCho or phosphatidylethanolamine. Th  
original description of the existence of a mammalian PLD 
focused upon the isoform that is an integral membrane pro- 
tein [1,2] and required the presence of an unsaturated fatty 
acid such as sodium oleate for in vitro measurements [3]. 
Another isoform of PLD requires a small molecular weight 
ARF  like GTP binding protein and PIP2 for in vitro measure- 
ments [4-9]. Therefore, it seemed of interest o determine if 
PIP2 and other acidic lipids could influence this neuronal PLD 
activity. We have characterized the properties of rat neuronal 
nuclear PLD [10]. This form requires the presence of sodium 
oleate for its measurement and is inhibited by both GTPyS or 
ATPyS. Therefore, it seemed of interest o determine if PIP2 
and other acidic lipids could influence this neuronal PLD 
activity. We have found that this neuronal nuclear PLD ac- 
tivity is inhibited by acidic phospholipids. 
2. Materials and methods 
Neuronal nuclei were isolated from rat brains according to a pub- 
lished procedure [11]. Protein content was quantitated by a classical 
method [12]. The incubations for the PLD activity measurements rou- 
tinely contained 50 mM dimethylglutarate pH 6.5, a substrate co- 
sonicate of 0.75 mM [14C]PtdCho and 1.2 mM sodium oleate, 10 
mM EDTA, 25 mM NaF and 20 lag nuclear protein. In the absence 
of ethanol the quantity of [14C]PtdA produced is a measure of the 
hydrolytic activity of PLD. In the presence of 0.3 M ethanol the sum 
of [14C]PtdA plus [14C]PtdEtOH produced is a measure of the trans- 
phosphatidylation activity of PLD [13,14]. The various acidic phos- 
*Corresponding author. Fax: (1) (204) 789 3500. 
Abbreviations." PLD, phospholipase D; PtdCho, phosphatidylcholine; 
PtdSer, phosphatidylserine; Ptdglycerol, phosphatidylglycerol; PtdE- 
tOH, phosphatidylethanol; PtdA, phosphatidic acid; PIP2, phospha- 
tidylinositol-4,5-diphosphate; P dlns, phosphatidylinositol; PLC, 
phospholipase C; ARF, ADP ribosylation factor. 
pholipids tested were prepared as a co-sonicate with the [14C]PtdCho 
and sodium oleate. The reaction was terminated after 1 h at 37°C and 
processed as previously described [15]. All incubations were in dupli- 
cate and each experiment was performed on at least 3 separate occa- 
sions. The hydrolytic activity of PLD is calculated as nmoles of PtdA 
formed in the absence of ethanol and transphosphatidylation activity 
expressed as nmol of PtdA + PtdEtOH formed in the presence of 
ethanol/mg protein/h +S.D. 
1,2-[14C]Dioleoyl PtdCho (spec. act. = 114 mCi/mmol) was pur- 
chased from Amersham Life Sciences, Oakville, Ontario, Canada, 
and mixed with authentic arrier to provide a final specific activity 
of 2800-3000 dpm/nmol. PIP2 was obtained from Fluka Chemika- 
BioChemika, Ronkonkoma, NY, USA. PtdSer, Ptdglycerol, cardio- 
lipin and PtdA were obtained from Serdary Research Laboratories, 
London, Ontario, Canada and phosphatidylethanol was obtained 
from Avanti Polar Lipids Inc., Alabaster, AL, USA. Silica gel 60 
TLC plates were obtained from Merck, Darmstadt, Germany. Reti- 
noic acid, cholesterol sulfate, dehydroisoandrosterone-3-sulfate, bis(2- 
ethylhexyl)hydrogen phosphate, 5-prenen-3[3-ol-20-one-sulfate, tauro- 
cholate and cholate were from Sigma-Aldrich Canada, Mississauga, 
Ontario, Canada. All other routine reagents were from the usual 
commercial suppliers. 
3. Results 
3.1. Inhibition by PtdA 
PtdA is one of the products of PLD hydrolysis of PtdCho 
and, therefore, a potential inhibitor of PLD activity due to 
product inhibition. A dose dependent inhibition by PtdA of 
both the hydrolytic activity, measured as PtdA formation and 
transphosphatidylation activity, measured as PtdA + PtdE- 
tOH formation, was observed (Fig. 1). 
3.2. Inhibition by PtdSer, Ptdglycerol and cardiolipin 
In order to learn if this inhibition by PtdA was a reflection 
of product inhibition and to establish the specificity, selected 
acidic phospholipids were tested. A dose dependent inhibition 
by PtdSer, Ptdglycerol and cardiolipin on the hydrolytic and 
the transphosphatidylation activity of the neuronal nuclear 
PLD is shown in Fig. 2. 
3.3. Inhibition by PIP2 
The presence of PIP2 is necessary for the in vitro assay of 
the small molecular weight GTP binding protein dependent 
PLD activity [4-9]. It was, therefore, surprising to find that 
there was a dose dependent inhibition of the oleate dependent 
PLD activity of neuronal nuclei as shown in Fig. 3. 
3.4. ICsos 
The IC50 values of PtdA, PtdSer, Ptdglycerol, cardiolipin 
and PIP2 for the inhibition of the neuronal nuclear PLD ac- 
tivity is presented in Table 1. It is apparent hat there are 
considerable differences in the inhibitory effectiveness of these 
acidic phospholipids. PIP2 is the most inhibitory and PtdA is 
the least inhibitory. 
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1 z g. 1. Inhibition of rat brain neuronal nuclear PLD activity by in- 
crzasing concentrations of PtdA. The experimental details are de- 
scribed in the text. The closed circles represent PtdA formation and 
tl~e open circles represents he sum of PtdA + PtdEtOH formation. 
3 5. Other anionic amphiphiles 
There was no inhibition of PLD activity by several anionic 
a~nphiphiles including retinoic acid, cholesterol sulfate, dehy- 
d -oisoandrosterone-3-sulfate, bis(2-ethylhexyl) hydrogen 
paosphate, 5-prenen-3[3-ol-20-one-sulfate, taurocholate or 
c ~olate. 
4 Discussion 
The presence of several acidic phospholipids in incubation 
ndxtures containing 0.75 mM PtdCho and 1.2 mM sodium 
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Fig. 2. Inhibition of rat brain neuronal nuclear PLD activity by in- 
creasing concentrations of PtdSer (upper panel), (lower panel) 
Ptdglycerol (circles) and cardiolipin (triangles). The experimental de- 
tails are described in the text. The closed symbols represent PtdA 
formation and the open symbols represents the sum of PtdA + 
PtdEtOH formation. 
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Fig. 3. Inhibition of rat brain neuronal nuclear PLD activity by in- 
creasing concentrations of PIP2. The experimental details are de- 
scribed in the text. The open circles represent PtdA formation, and 
the closed circles represent the sum of PtdAS + PtdEtOH forma- 
tion. 
PLD. The inhibition by PtdA was expected based upon the 
general principle of product inhibition. The basis for the in- 
hibition by the other acidic phospholipids i not readily un- 
derstood. It cannot be due to the negative charge per se since 
these phospholipids were added as their sodium salts and 
there is routinely present many fold greater amounts of so- 
dium oleate in the incubation mixtures. The inhibitory activity 
of acidic phospholipids upon enzymatic reactions has been 
observed. A 34 000 fold purified bovine testicular diacylglycer- 
ol kinase was inhibited by PtdSer [16]. The activity of a 3500 
fold purified human lymphoblastic N-acetylglucosamine-1- 
phosphotransferase was inhibited by PtdSer, Ptdglycerol and 
PtdA [17]. The PtdIns specific PLC activity of pancreatic islet 
cells was inhibited by PtdSer [18]. A soluble PtdA phospho- 
hydrolase from rat liver was inhibited by Ptdglycerol, PtdSer 
and PtdIns [19]. A partially purified CDP-diacylglycerol 
synthetase from bovine brain was inhibited by cardiolipin 
[20]. Rat brain hexokinase activity was inhibited by PtdIns, 
PtdSer and cardiolipin [21]. Therefore, a diversity of enzymes 
are inhibited by acidic phospholipids with little specificity. 
The ICs0 values for the 5 acidic phospholipids employed in 
these studies ranged from 3.5 ~tM to 200 ~M. The most potent 
was PIP2 at 0.4 to 0.8 mole% ratio compared to PtdCho 
present. This is a range of PIP2 present in mammalian tissues 
and reported to stimulate the ARF dependent PLD [22]. It, 
therefore, is reasonable to speculate that any stimulation of 
the hydrolysis of PIP2 by PIP2-PLC would result in reduced 
ARF dependent PLD activity and in increased oleate depen- 
dent PLD activity. It has been suggested that PIP2 acts as a 
cofactor for ARF interactions with proteins [23,24]. Hydro- 
lysis would reduce the quantity of PIP2 available as cofactor 
for these ARF interactions. The reduction of PIPz content 
would be expected to disinhibit the oleate dependent PLD. 
This reciprocal relationship would provide a control mechan- 
ism for allowing either the small molecular weight G protein 
dependent PLD or the oleate dependent PLD linked processes 
to proceed. Agonist stimulated PLD activity subsequent to 
PIP2-PLC activation has been reported [25 27]. The hydroly- 
sis of PIP2 by PLC produces a diglyceride directly, the hydro- 
lysis of PtdCho by PLD produces a PtdA which is hydrolysed 
by a PtdA phosphatase to diglyceride. The receptor mediated 
biphasic diglyceride formation with differences in their time of 
appearance, duration and molecular species have been ob- 
served. These investigations have identified PIP2 as the source 
of the rapidly appearing short duration diglyceride. PtdCho is 
Table 1 
The IC50 values for inhibition of rat brain neuronal nuclear PLD 
by PtdSer, PtdA, Ptdglycerol, cardiolipin and PIP2 
IC50 of acidic phospholipids (I.tM) 
PtdA(-EtOH) PtdA+ PtdEtOH 
(+EtOH) ~ 
PtdSer 49 60 
PtdA 200 180 
Ptdglycerol 97 75 
Cardiolipin 20 17 
PIP2 6 3.5 
The details are provided in the text. 
a0.3 M EtOH was present in these incubation mixtures. 
the source of the later appearing, sustained uration diglycer- 
ide [28]. 
This phenomenon supports the speculation that the hydro- 
lysis of PIP2 by PLC releases the PIP2 inhibition of the oleate 
dependent PLD. 
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